All In Biotech

Drug Trial Radar · NCT03242252

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control

Last checked: Nov 20, 2026Latest source record: Jun 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 787 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

787

Actual

Start

Aug 16, 2017

Primary completion

Mar 25, 2019

Study completion Oct 25, 2019

Sponsor

Lead sponsor
Lexicon PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Sanofi
First posted
Aug 8, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To demonstrate the superiority of Sotagliflozin 200 milligrams (mg) and Sotagliflozin 400 mg versus placebo on HbA1c reduction at 26 Weeks in participants with Type 2 diabetes who have inadequate glycemic control and moderate renal impairment. Secondary Objectives: * To assess the effects of Sotagliflozin 200 mg and 400 mg versus placebo with respect to additional measures of glycemic control, blood pressure, and body weight. * To evaluate the safety of Sotagliflozin 200 mg and 400 mg versus placebo.

Conditions

  • Type 2 Diabetes Mellitus
  • Chronic Kidney Disease Stage 3

Interventions

  • PlaceboDrug

    Placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily. Route of administration: Oral

  • SotagliflozinDrug

    Sotagliflozin 200 mg, tablet, orally once daily. Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in HbA1c at Week 26Time frame: Baseline to Week 26

Locations

170 sites in 16 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 8404018

    Birmingham, Alabama

  • Investigational Site Number 8404045

    Guntersville, Alabama

  • Investigational Site Number 8404004

    Phoenix, Arizona

  • Investigational Site Number 8404022

    Phoenix, Arizona

  • Investigational Site Number 8404007

    Little Rock, Arkansas

  • Investigational Site Number 8404023

    Chula Vista, California

  • Investigational Site Number 8404044

    Gold River, California

  • Investigational Site Number 8404011

    Los Angeles, California

  • Investigational Site Number 8404003

    Norco, California

  • Investigational Site Number 8404025

    Northridge, California

  • Investigational Site Number 8404038

    San Dimas, California

  • Investigational Site Number 8404019

    Clearwater, Florida

  • Investigational Site Number 8404001

    DeLand, Florida

  • Investigational Site Number 8404006

    Ocoee, Florida

  • Investigational Site Number 8404064

    Orlando, Florida

  • Investigational Site Number 8404043

    Ormond Beach, Florida

  • Investigational Site Number 8404013

    Palmetto Bay, Florida

  • Investigational Site Number 8404016

    Savannah, Georgia

  • Investigational Site Number 8404040

    Wauconda, Illinois

  • Investigational Site Number 8404036

    Lake Charles, Louisiana

  • Investigational Site Number 8404020

    New Orleans, Louisiana

  • Investigational Site Number 8404014

    Norfolk, Nebraska

  • Investigational Site Number 8404032

    Papillion, Nebraska

  • Investigational Site Number 8404048

    Hackensack, New Jersey

  • Investigational Site Number 8404074

    New York, New York

  • Investigational Site Number 8404009

    The Bronx, New York

  • Investigational Site Number 8404051

    Wilmington, North Carolina

  • Investigational Site Number 8404028

    Winston-Salem, North Carolina

  • Investigational Site Number 8404029

    Winston-Salem, North Carolina

  • Investigational Site Number 8404026

    Dayton, Ohio

  • Investigational Site Number 8404052

    Lansdale, Pennsylvania

  • Investigational Site Number 8404031

    Anderson, South Carolina

  • Investigational Site Number 8404021

    Mt. Pleasant, South Carolina

  • Investigational Site Number 8404056

    Chattanooga, Tennessee

  • Investigational Site Number 8404015

    Austin, Texas

  • Investigational Site Number 8404050

    Austin, Texas

  • Investigational Site Number 8404060

    Austin, Texas

  • Investigational Site Number 8404005

    Beaumont, Texas

  • Investigational Site Number 8404035

    Dallas, Texas

  • Investigational Site Number 8404039

    Houston, Texas

Showing 40 of 170 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.